-
Pertussis, commonly known as the "whooping cough," is an infection of the upper respiratory tract leading to a protracted cough illness. Emergency physicians should become familiar with the diagnosis and management of this disease, given the potential of pertussis to cause serious morbidity and mortality in young infants and protracted illness in adolescents and adults. Furthermore, diagnosing and treating pertussis in a timely manner has a large public health impact, given its extremely contagious nature.
-
-
Both vitamin D deficiency and supplementation with vitamin D are significantly associated with several cardiovascular outcomes, including mortality.
-
The first results of a 5-year study of the effects a mindfulness-based stress reduction program on medical complications and psychosocial outcomes in patients with type 2 diabetes show prolonged reduction in psychological distress and depression compared to usual care.
-
This ProMED-mail alert describes the case of a young Rhode Island resident who traveled to Cambodia and Viet Nam, where she was hospitalized with spinal cord compression in December 2011.
-
A total of 1745 infants from 17 sites in Brazil (70.1%), South Africa (27.4%), Argentina (1.6%) and the United States (0.8%) born to women with a peripartum diagnosis of HIV type I infection were randomized within 48 hours of birth to receive one of three six-week postpartum antiretroviral regimens.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
FoodNet is an active surveillance program that collects data on 9 laboratory-confirmed pathogens from 10 sites in the United States: 7 states (Connecticut, Georgia, Maryland, Minnesota, New Mexico, Oregon, and Tennessee) and certain counties in California, Colorado, and New York.
-
The U.S. Food and Drug Administration (FDA) recently issued an alert on the potential risk of non-convulsive status epilepticus associated with the use of cefepime, a broad spectrum fourth generation cephalosporin.
-
On 15 May the FDA Center for Biologics Evaluation and Research/Office of Blood Research and Review (CBER/OBRR) granted market clearance to the OraQuick in-home HIV-1/2 antibody test based on the recommendation of the Blood Products Advisory Committee.